| Registry No. |
Drug |
Targeted Gene |
Indications |
Phase of Trial |
| Gene expression |
| NCT01024998 |
AAV2-sFLT01 |
sFLT |
AMD |
Phase I |
| NCT01494805 |
rAAV.sFlt-1 |
sFLT |
AMD |
Phase I |
| NCT00109499 |
AdGVPEDF.11D |
PEDF |
Macular degeneration |
Phase I |
| NCT01301443 |
RetinoStat |
EndostatinAngiostatin |
AMD |
Phase I |
| Antisense oligonucleotides |
| GS101-P3-CG
(EudraCT) |
GS-101 |
IRS-1 |
CNV |
phase III |
| siRNA |
| NCT00722384
NCT00259753
NCT00499590 |
Bevasiranib |
VEGF |
Macular degeneration |
Phase I
Phase II
Phase III |
| NCT00557791 |
Bevasiranib |
VEGF |
AMD |
Phase III |
| NCT00363714 |
AGN211745
(siRNA-027) |
VEGF receptor |
Choroidal NV
AMD |
Phase II
Phase I |
| NCT00395057 |
AGN211745
(siRNA-027) |
VEGF receptor |
Choroidal NV
AMD |
Phase II |
| NCT01445899 |
PF-04523655 |
RTP801 |
Choroidal NV |
Phase II |
| NCT00725686 |
PF-04523655 |
RTP801 |
AMD |
Phase I |
| miRNA |
| (none) |
|
